全文获取类型
收费全文 | 964篇 |
免费 | 51篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 68篇 |
妇产科学 | 5篇 |
基础医学 | 123篇 |
口腔科学 | 29篇 |
临床医学 | 131篇 |
内科学 | 216篇 |
皮肤病学 | 23篇 |
神经病学 | 23篇 |
特种医学 | 185篇 |
外科学 | 55篇 |
综合类 | 24篇 |
预防医学 | 56篇 |
眼科学 | 14篇 |
药学 | 60篇 |
中国医学 | 1篇 |
肿瘤学 | 33篇 |
出版年
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 8篇 |
2019年 | 10篇 |
2018年 | 21篇 |
2017年 | 19篇 |
2016年 | 14篇 |
2015年 | 18篇 |
2014年 | 17篇 |
2013年 | 36篇 |
2012年 | 32篇 |
2011年 | 28篇 |
2010年 | 45篇 |
2009年 | 42篇 |
2008年 | 36篇 |
2007年 | 32篇 |
2006年 | 29篇 |
2005年 | 42篇 |
2004年 | 18篇 |
2003年 | 4篇 |
2002年 | 14篇 |
2001年 | 19篇 |
2000年 | 14篇 |
1999年 | 20篇 |
1998年 | 52篇 |
1997年 | 46篇 |
1996年 | 49篇 |
1995年 | 34篇 |
1994年 | 41篇 |
1993年 | 36篇 |
1992年 | 18篇 |
1991年 | 18篇 |
1990年 | 11篇 |
1989年 | 22篇 |
1988年 | 46篇 |
1987年 | 20篇 |
1986年 | 17篇 |
1985年 | 31篇 |
1984年 | 8篇 |
1983年 | 3篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 12篇 |
1975年 | 4篇 |
1973年 | 1篇 |
1971年 | 2篇 |
排序方式: 共有1051条查询结果,搜索用时 15 毫秒
101.
Susanne Juhl Pedersen Merete Lund Hetland Inge Juul Sørensen Mikkel Østergaard Hans Jørgen Nielsen Julia Sidenius Johansen 《Clinical rheumatology》2010,29(11):1301-1309
The objectives of the study were to investigate short and long-term changes and relations to treatment response of plasma
interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), YKL-40, matrix metalloproteinase-3 (MMP-3), and total aggrecan
in patients with spondyloarthritis (SpA) treated with tumor necrosis factor-alpha (TNFα) inhibitors and to compare with levels
in healthy subjects. Biomarkers were measured in an observational cohort of 49 SpA patients (ankylosing spondylitis, n = 32, and psoriatic arthritis, n = 17) initiating TNFα inhibitor therapy (infliximab, n = 38; etanercept, n = 8; and adalimumab, n = 3) and compared with levels in healthy subjects. Clinical parameters and biomarkers were measured at baseline, weeks 2,
6, and every 6–12 weeks for up to 3 years. Patients with co-morbidities (n = 4), missing baseline samples (n = 3), and adverse events (n = 5) were excluded. Patients with SpA had compared with healthy subjects elevated IL-6 (median 8.5 ng/l (range, 0.98–64)
vs. 1.3 (0.33–26)), VEGF (105 ng/l (22–752) vs. 45 (12–351)), YKL-40 (74 μg/l (14–572) vs. 43 (20–184)), and MMP-3 (43 μg/l
(9.1–401) vs. 16 (2.5–47), p ≤ 0.001), whereas total aggrecan was lower (662 μg/l (223–2,219) vs. 816 (399–2,190),p ≤ 0.001). Two weeks after first treatment, all biomarker levels changed towards normal levels (p ≤ 0.03) in clinical responders (n = 24), and persistent reductions over 3 years were found in IL-6, VEGF, YKL-40, and MMP-3. Only MMP-3 decreased (p ≤ 0.02) in non-responders (n = 13). The study demonstrated changes of plasma IL-6, VEGF, YKL-40, MMP-3, and total aggrecan and a potential value for monitoring
disease activity and treatment response in SpA patients. Larger prospective studies are required to clarify clinical utility
of these biomarkers. 相似文献
102.
103.
Vita W Jongen Thijs Reyniers Zorah MH Ypma Maarten F Schim van der Loeff Udi Davidovich Hanne ML Zimmermann Liza Coyer Mark AM van den Elshout Henry JC de Vries Kristien Wouters Tom Smekens Bea Vuylsteke Maria Prins Marie Laga Elske Hoornenborg 《Journal of the International AIDS Society》2021,24(8)
IntroductionDaily and event‐driven PrEP are both efficacious in reducing the risk for HIV infection. However, the practice of event‐driven PrEP (edPrEP) is less well studied, in particular when provided as an alternative to daily PrEP. We studied regimen preferences and switches, and sexually transmitted infection (STI) incidence.MethodsWe analysed pooled data from two prospective cohort studies among MSM: Be‐PrEP‐ared, Belgium and AMPrEP, the Netherlands. In both projects, participants could choose between daily and edPrEP at three‐monthly study visits, when they were also screened for sexually transmitted infections including hepatitis C (HCV). We assessed the proportion choosing each regimen, and the determinants of choosing edPrEP at baseline. Additionally, we compared the incidence rates (IRs) of HCV, syphilis and chlamydia or gonorrhoea between regimens using Poisson regression. The study period was from 3 August 2015 until 24 September 2018.Results and discussionWe included 571 MSM, of whom 148 (25.9%) chose edPrEP at baseline. 31.7% of participants switched regimen at least once. After 28 months, 23.5% used edPrEP. Older participants (adjusted odds ratio (aOR) = 1.38 per 10 years, 95% confidence interval (CI) = 1.15 to 1.64) and those unemployed (aOR = 1.68, 95% CI = 1.03 to 1.75) were more likely to initially choose edPrEP. IR of HCV and syphilis did not differ between regimens, but the IR of chlamydia/gonorrhoea was higher among daily users (adjusted incidence rate ratio = 1.61, 95% CI = 1.35 to 1.94).ConclusionsA quarter of participants chose edPrEP at baseline and at 28 months this proportion was similar. Although the IR of HCV and syphilis were similar in the two regimens, the lower incidence of chlamydia and gonorrhoea among edPrEP users may suggest that less frequent STI testing of this group could be considered. 相似文献
104.
105.
GM Repetto ML Guzmán A Puga JF Calderón CP Astete M Aracena M Arriaza T Aravena P Sanz 《Clinical genetics》2009,76(5):465-470
Patients with chromosome 22q11 deletion syndrome exhibit significant phenotypic variability. Epidemiologic data suggest a higher incidence in Hispanics, but limited clinical information is available from Latin-American patients. We describe the clinical features of Chilean patients with 22q11 deletion syndrome and compare their findings with those reported in large European, Japanese and US series. Data were obtained from 208 patients from five medical centers. Mean age at diagnosis was 5.2 years, with a median of 2.3 years. Congenital heart defects were present in 59.6%, lower than other large series that averaged 75.8%. Palate abnormalities were present in 79%, higher than previous reports averaging 56%. Patients with congenital heart disease were diagnosed earlier (median 0.3 years of age) than those without heart defects (median 5.6 years) and had greater mortality attributable to the syndrome (9.8% vs 2.4%, respectively). The differences in frequencies of major anomalies may be due to growing awareness of more subtle manifestations of the syndrome, differences in clinical ascertainment or the presence of modifier factors. These observations provide additional data useful for patient counseling and for the proposal of health care guidelines. 相似文献
106.
107.
108.
109.
D Gómez-Garre P Mu?oz-Pacheco ML González-Rubio P Aragoncillo R Granados A Fernández-Cruz 《British journal of pharmacology》2009,156(8):1218-1227